Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars
Christine Berndt Previously Headed Biosimilar Development Programs At Sandoz
Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.
You may also be interested in...
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.
Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.